118
Participants
Start Date
April 4, 2019
Primary Completion Date
July 1, 2020
Study Completion Date
December 30, 2020
OxyCODONE 5 Mg (milligram) Oral Tablet
Oxycodone will be the second-line treatment in the control group and the third-line treatment in the experimental group.
Ibuprofen 600 Mg (milligram) Oral Tablet
Patients in the experimental group will receive ibuprofen 600mg as the second-line analgesic.
Acetaminophen 650 MG (milligram) Oral Tablet
All patients will receive acetaminophen as the first-line analgesic.
Albert Einstein, The Bronx
Vanderbilt, Nashville
Mayo Clinic, Rochester
NorthShore University Health System, Evanston
Stanford Health Care, Stanford
University of British Columbia, Vancouver
Collaborators (2)
Mayo Clinic
OTHER
Vanderbilt University Medical Center
OTHER
Albert Einstein College of Medicine
OTHER
University of British Columbia
OTHER
Endeavor Health
OTHER
Stanford University
OTHER